PCSK9 and hyperlipidemia: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a transformative therapy for patients with high cardiovascular risk or refractory hyperlipidemia, providing substantial LDL-C reduction and improving cardiovascular outcomes.